Overall efficacy based on underlying factors (all randomized patients)

Underlying factorFavorable outcome
Persistent febrile neutropenia (n/total)Refractory disease (n[CR:PR]h/total)
Efficacy evaluable (n = 53)All randomized (n = 66)Efficacy evaluable (n = 21)All randomized (n = 32)
Underlying diseasea
    Non-Hodgkin's lymphoma6/76/80/10/1
    Myelodysplastic syndrome2/52/61[0:1]/31[0:1]/4
    Aplastic anemia2/32/40/00/0
Transplantation history
    Allogeneic BMT5/76/92[1:1]/54[2:2]/12
    Solid-organ transplant0/00/00/00/0
    Aspergillus spp.0/01/12[1:1]/104[2:2]/17
    Fusarium spp.0/00/02[0:2]/22[0:2]/3
Site of infection0/0e2/3f9[2:7]/2111[3:8]/32
Neutropenic status41/5342/669[2:7]/2111[3:8]/32
    ANC ≤500 cells/μl involvement38/4939/601[0:1]/22[1:1]/3
    ANC >500 cells/μl2/32/38[2:6]/159[2:7]/21
  • a Patients could have had more than one underlying condition.

  • b Other underlying diseases were Hodgkin's disease (n = 1) and malignant testis neoplasm (n = 1).

  • c Other underlying diseases were Hodgkin's disease (n = 1), malignant testis neoplasm (n = 1), and neoplasm not otherwise specified (n = 1).

  • d Other underlying disease was malignant breast neoplasm (n = 1).

  • e One efficacy-evaluable patient had nonpulmonary (perianal) Geotrichum infection 3 days after posaconazole discontinuation and was not included in the analysis.

  • f Only three all-randomized patients had possible IFI during posaconazole treatment.

  • g Other pathogens were not specified.

  • h CR, complete response; PR, partial response.